Loss of SOX2 function promotes cell motility of head and neck cancer cells.
Tumor cells exhibit inverse expression of SOX2 and vimentin both in vitro and in vivo.
Vimentin down-regulation partially reverts accelerated motility after SOX2 silencing.
Low SOX2 protein levels are correlated with patient poor clinical outcome.
SOX2 serves as an independent prognostic biomarker for treatment failure.